Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 105

1.

Unfavourable outcomes among patients with MDR-TB on the standard 24-month regimen in Maharashtra, India.

Suryawanshi SL, Shewade HD, Nagaraja SB, Nair SA, Parmar M.

Public Health Action. 2017 Jun 21;7(2):116-122. doi: 10.5588/pha.17.0013.

2.

A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Handelsman Y, Lauring B, Gantz I, Iredale C, O'Neill EA, Wei Z, Suryawanshi S, Kaufman KD, Engel SS, Lai E.

Curr Med Res Opin. 2017 Jun 28:1-8. doi: 10.1080/03007995.2017.1335638. [Epub ahead of print]

PMID:
28548024
3.

A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.

Shankar RR, Inzucchi SE, Scarabello V, Gantz I, Kaufman KD, Lai E, Ceesay P, Suryawanshi S, Engel SS.

Curr Med Res Opin. 2017 Jun 23:1-8. doi: 10.1080/03007995.2017.1335637. [Epub ahead of print]

PMID:
28547998
4.

Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors.

Zhao X, Suryawanshi S, Hruska M, Feng Y, Wang X, Shen J, Vezina HE, McHenry MB, Waxman IM, Achanta A, Bello A, Roy A, Agrawal S.

Ann Oncol. 2017 May 17. doi: 10.1093/annonc/mdx235. [Epub ahead of print]

PMID:
28520840
5.

Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

Wong H, Bohnert T, Damian-Iordache V, Gibson C, Hsu CP, Krishnatry AS, Liederer BM, Lin J, Lu Q, Mettetal JT, Mudra DR, Nijsen MJMA, Schroeder P, Schuck E, Suryawanshi S, Trapa P, Tsai A, Wang H, Wu F.

Drug Discov Today. 2017 May 2. pii: S1359-6446(17)30002-8. doi: 10.1016/j.drudis.2017.04.015. [Epub ahead of print]

PMID:
28476536
6.

Carbazole based nanoprobe for selective recognition of Fe3+ ion in aqueous medium: Spectroscopic insight.

Suryawanshi SB, Mahajan PG, Bodake AJ, Kolekar GB, Patil SR.

Spectrochim Acta A Mol Biomol Spectrosc. 2017 Aug 5;183:232-238. doi: 10.1016/j.saa.2017.04.010. Epub 2017 Apr 18.

PMID:
28454076
7.

A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.

Chacra A, Gantz I, Mendizabal G, Durlach L, O'Neill EA, Zimmer Z, Suryawanshi S, Engel SS, Lai E.

Int J Clin Pract. 2017 Jun;71(6). doi: 10.1111/ijcp.12955. Epub 2017 Apr 27.

PMID:
28449320
8.

Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.

Engel SS, Suryawanshi S, Stevens SR, Josse RG, Cornel JH, Jakuboniene N, Riefflin A, Tankova T, Wainstein J, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Obes Metab. 2017 Apr 22. doi: 10.1111/dom.12983. [Epub ahead of print]

PMID:
28432745
9.
10.

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5.

PMID:
28057693
11.

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.

Segal NH, Logan TF, Hodi FS, McDermott D, Melero I, Hamid O, Schmidt H, Robert C, Chiarion-Sileni V, Ascierto PA, Maio M, Urba WJ, Gangadhar TC, Suryawanshi S, Neely J, Jure-Kunkel M, Krishnan S, Kohrt H, Sznol M, Levy R.

Clin Cancer Res. 2017 Apr 15;23(8):1929-1936. doi: 10.1158/1078-0432.CCR-16-1272. Epub 2016 Oct 18.

PMID:
27756788
12.

Gossypiboma: An Unusual Presentation as Perforation and Intraluminal Migration.

Tiwari VK, Mahey RK, Patil R, Bakale N, Suryawanshi S.

J Clin Diagn Res. 2016 Sep;10(9):PD01-PD02. Epub 2016 Sep 1.

13.

Identification and quantification of indoor air pollutant sources within a residential academic campus.

Suryawanshi S, Chauhan AS, Verma R, Gupta T.

Sci Total Environ. 2016 Nov 1;569-570:46-52. doi: 10.1016/j.scitotenv.2016.06.061. Epub 2016 Jun 18.

PMID:
27328399
14.

Fully Synthetic Self-Adjuvanting α-2,9-Oligosialic Acid Based Conjugate Vaccines against Group C Meningitis.

Liao G, Zhou Z, Suryawanshi S, Mondal MA, Guo Z.

ACS Cent Sci. 2016 Apr 27;2(4):210-8. doi: 10.1021/acscentsci.5b00364. Epub 2016 Apr 4.

15.

Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, Solomon SD, Greenlaw N, Ali MA, Chiang Y, Shao Q, Tarnesby G, Massie BM; ATMOSPHERE Committees Investigators.

N Engl J Med. 2016 Apr 21;374(16):1521-32. doi: 10.1056/NEJMoa1514859. Epub 2016 Apr 4.

16.

A Fully Synthetic Self-Adjuvanting Globo H-Based Vaccine Elicited Strong T Cell-Mediated Antitumor Immunity.

Zhou Z, Liao G, Mandal SS, Suryawanshi S, Guo Z.

Chem Sci. 2015 Dec 1;6(12):7112-7121. Epub 2015 Sep 22.

17.

Antibiotic Prescribing Pattern in a Tertiary Level Neonatal Intensive Care Unit.

Suryawanshi S, Pandit V, Suryawanshi P, Panditrao A.

J Clin Diagn Res. 2015 Nov;9(11):FC21-4. doi: 10.7860/JCDR/2015/14764.6807. Epub 2015 Nov 1.

18.

Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.

Sheu WH, Gantz I, Chen M, Suryawanshi S, Mirza A, Goldstein BJ, Kaufman KD, Engel SS.

Diabetes Care. 2015 Nov;38(11):2106-14. doi: 10.2337/dc15-0109. Epub 2015 Aug 26.

PMID:
26310692
19.

Preclinical evaluation of SMM-189, a cannabinoid receptor 2-specific inverse agonist.

Presley C, Abidi A, Suryawanshi S, Mustafa S, Meibohm B, Moore BM.

Pharmacol Res Perspect. 2015 Aug;3(4):e00159. doi: 10.1002/prp2.159. Epub 2015 Jul 6.

20.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group.

N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8. Erratum in: N Engl J Med. 2015 Aug 6;373(6):586.

Supplemental Content

Loading ...
Support Center